文献速递肝病消化道肿瘤与早癌

代偿期肝硬化乙型肝炎病毒相关肝细胞癌患者切除术后抗病毒治疗的成本效益

Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
PubMed 文献 · Hepatology · 2018-05-14

本研究构建马尔可夫模型,模拟乙型肝炎病毒相关肝细胞癌合并代偿期肝硬化且HBV DNA可检测的患者,比较切除术后核苷(酸)类似物治疗与不治疗的成本效益。核苷(酸)类似物治疗获得4.22质量调整生命年、花费39898美元,不治疗获得2.80质量调整生命年、花费16048美元,增量成本效益比为16848美元/质量调整生命年,概率敏感性分析显示具有成本效益的概率为0.852。

要点

  • 核苷(酸)类似物治疗获得4.22 QALYs,不治疗获得2.80 QALYs。
  • 核苷(酸)类似物治疗花费39898美元,不治疗花费16048美元。
  • 增量成本效益比为16848美元/QALY,概率敏感性分析具有成本效益的概率为0.852。

核心结论

  • 肝切除术后核苷(酸)类似物治疗在乙型肝炎病毒相关肝细胞癌合并代偿期肝硬化患者中可能具有成本效益。

研究设计与样本

  • 构建马尔可夫模型,模拟乙型肝炎病毒相关肝细胞癌合并代偿期肝硬化且HBV DNA可检测的患者,比较切除术后接受或不接受核苷(酸)类似物治疗,并随访终生。
  • 从社会视角计算每种策略的成本、预期寿命、质量调整生命年和增量成本效益比,模型参数来源于已发表研究、政府文件和调查,并进行敏感性分析。

主要发现

  • 核苷(酸)类似物治疗获得4.22质量调整生命年,花费39898美元。
  • 不治疗获得2.80质量调整生命年,花费16048美元。
  • 核苷(酸)类似物治疗相对于不治疗的增量成本效益比为16848美元/质量调整生命年,介于人均国内生产总值的2至3倍之间,因此被认为具有成本效益。
  • 概率敏感性分析证实核苷(酸)类似物治疗具有成本效益,概率为0.852。

关键数值与推荐

  • 中国指南推荐乙型肝炎病毒相关肝细胞癌切除术后接受核苷(酸)类似物抗病毒治疗。
  • 增量成本效益比16848美元/质量调整生命年介于人均国内生产总值的2至3倍之间,被认为具有成本效益。

临床怎么用

  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV-related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines. However, cost-effectiveness studies regarding this treatment are rare. The objective of this study was to estimate the cost-effectiveness of NA treatment after resection in HBV-related HCC patients with compensated cirrhosis. A Markov model was constructed to simulate HBV-related HCC patients with compensated cirrhosis and detectable HBV DNA, with or without NA treatment after resection, followed up over their lifetime. Costs, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER) were calculated for each strategy from the societal perspective. The parameters of the model were derived from published studies, government documents, and our surveys. Sensitivity analyses were used to explore the impact of parameters on the uncertainty of the results. NA treatment produced 4.22 QALYs, costing $39,898, while non-NA treatment achieved 2.80 QALYs, costing $16,048. The ICER of NA treatment versus non-NA treatment was $16,848/QALY, which was between 2 and 3 times gross domestic product per capita and was therefore deemed cost-effective. Probabilistic sensitivity analysis confirmed that NA treatment was cost-effective, with a probability of 0.852. CONCLUSION: NA treatment after liver resection was likely cost-effective in HBV-related HCC patients with compensated cirrhosis. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Xie L, Yin J, Xia R, et al. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology. 2018. PMID: 29633304. doi:10.1002/hep.29922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。